AzTrials
AzTrials

Third Molar ExtractionPhase 3NCT00971178

Analgesic Effect of Peripheral Dexmedetomidine

A Phase 3 study testing local dexmedetomidine, Peripheral normal saline and IV dexmedetomidine in people with Third Molar Extraction, run by The University of Hong Kong.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Dexmedetomidine is an alpha 2-adrenoreceptor agonist, which provides sedation, analgesia and anxiolysis in clinical practice (Cortinez et al., 2004,Hall et al., 2000). Three types of alpha 2-adrenergic receptor subtypes are found in the human body and they have been designated alpha 2A, alpha 2B and alpha 2C. Read more about this study

Who is it for?
Ages 18 to 50 years
Conditions the study is for
Third Molar Extraction
What is being tested?
local dexmedetomidine, Peripheral normal saline and IV dexmedetomidine
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
105 participants
Where
No sites listed yet
Study dates
Feb 2006to Mar 2008
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • American Society of Anesthesiologists (ASA) physical status I and II
  • Age between 18 and 50 years of age with 4 bilateral impacted third molar teeth scheduled for extraction under general anaesthesia

Who cannot join

  • Clinical history or electrocardiographic evidence of heart block
  • Ischaemic heart disease
  • Asthma
  • Sleep apnoea syndrome
  • Impaired liver or renal function
  • Alcohol consumption in excess of 28 units per week
Show all 11Show fewer
  • Pregnancy
  • Patient refusal
  • Known psychiatric illness
  • Chronic sedative or analgesic use, and regular use of or known allergy to dexmedetomidine, paracetamol or dextropropoxypheneopioids
  • Patients with preoperative inflammation at the site of surgery were also excluded

About this study

Official title: Effectiveness of Peripheral Dexmedetomidine for Bilateral Third Molar Surgery Under General Anaesthesia

Dexmedetomidine is an alpha 2-adrenoreceptor agonist, which provides sedation, analgesia and anxiolysis in clinical practice (Cortinez et al., 2004,Hall et al., 2000). Three types of alpha 2-adrenergic receptor subtypes are found in the human body and they have been designated alpha 2A, alpha 2B and alpha 2C. The alpha 2A subtype is most likely responsible for the analgesic properties of dexmedetomidine in both peripheral and central sites (Kingery et al., 2000, Smith et al., 2001). Activation of central alpha 2-adrenoreceptors in the locus ceruleus (Correa-Sales et al., 1992) and the dorsal horn of the spinal cord (Gaumann et al., 1992b) are responsible for both analgesic and sedative effects. Dexmedetomidine has a very high alpha 2 to alpha 1 selectivity, 1620 to 1, or approximately 8 times that of clonidine. It is also 4 to 6 times more potent than clonidine by weight (Bhana et al., 2000).

Although dexmedetomidine produces dose dependent sedation upon intravenous administration, its the analgesic effect is of dexmedetomidine is more variable and controversial. In an ischaemic pain model in healthy volunteers, a single bolus of dexmedetomidine produced a 50% reduction in pain scores when compared to placebo (Jaakola et al., 1991). In another volunteer study using the cold pressor test, dexmedetomidine 1 µg/kg over 10 minutes followed by an infusion of 0.2 to 0.6 µg/kg/hour reduced pain by approximately 30% (Hall et al., 2000). However, when administered as a target controlled infusion at concentrations ranging from 0.09 to 1.23 ng/mL, dexmedetomidine had no analgesic effect in human volunteers subjected to heat and electrical pain, although sedation was produced (Memis et al., 2004).

Clonidine and dexmedetomidine are two common alpha 2 agonists used clinically. Although clonidine former has been used successfully in regional analgesia and anesthesia (Gabriel et al., 2001)., There are only very few studies evaluating the peripheral analgesic effects of dexmedetomidine. Since acute postoperative dental pain is a common analgesia model (Cooper, 1991; US Food and Drug Administration 1992), the investigators conducted this study, aiming to assess the postoperative analgesic efficacy of peripheral dexmedetomidine after bilateral third molar surgery under general anaesthesia. The analgesic effects were compared up to the 72nd hour postoperatively in order to evaluate any potential preventive analgesic effect.

Read the detailed description

The study protocol was approved by our local Institutional Review Board and written consent was obtained from all the participants. Eligibility for recruitment included American Society of Anesthesiologists (ASA) physical status I and II, age between 18 and 50 years of age with 4 bilateral impacted third molar teeth scheduled for extraction under general anaesthesia. Exclusion criteria included clinical history or electrocardiographic evidence of heart block, ischaemic heart disease, asthma, sleep apnoea syndrome, impaired liver or renal function, alcohol consumption in excess of 28 units per week, pregnancy, patient refusal, known psychiatric illness, chronic sedative or analgesic use, and regular use of or known allergy to dexmedetomidine, paracetamol or dextropropoxypheneopioids. Patients with preoperative inflammation at the site of surgery were also excluded.

After obtaining written, informed consent, patients were randomly allocated to receive 1)Preoperative IV dexmedetomidine 1mcg/kg and normal saline infiltrated to wound at the end of surgery; 2) Preoperative normal saline IV infusion and dexmedetomidine 1mcg/kg infiltrated to wound or 3) Preoperative IV normal saline infusion and normal saline infiltrated to wound at the end of surgery. A computer generated random sequence was used for drug allocation and this was prepared by a statistician who was unaware of the clinical nature of the study. The patients were assessed by the list anaesthetist the day before surgery. They were fasted for at least 6 hours and did not receive any premedication before arrival at the operation theatre. Patients were educated on the use of the Numerical Rating Scale (NRS) for pain assessment, where zero corresponds to no pain and 10 represents the worst pain imaginable.

A P-deletion test was performed in the ward preoperatively. The P-deletionThis test consists of 58 lines of closely typed text containing between 74 to 97 occurrences of the letter "p". The patients are instructed to cross out every letter "p" they can find as quickly as possible, reading from left to right down the page. The number deleted in 180 seconds and the number of errors counts. This test assesses speed, accuracy, concentration, mental activity, hand-eye coordination and vigilance. It was firstly described by Dixon and colleagues who found it to be an accurate test for psychomotor recovery from anesthesia and sedation (Dixon et al., 1973).

On arrival at the operating theatre, a 20-gauge intravenous cannula was inserted in the dorsum of each patient's left hand. Either dexmedetomidine 1 µg/kg (Group D) diluted to 4ml with normal saline or the same volume of 0.9% saline alone (Group P) was prepared by another anaesthetist who did not participate in patient management or data collection. Both preparations were clear solutions, therefore patients, medical, nursing staff, and data collectors were all blinded to the allocated drug. Heart rate, blood pressure, respiratory rate and oxygen saturation were recorded (S/5 Anesthesia Monitor, Datex-Ohmeda, WI, USA) before general anaesthesia and thereafter at five-minute intervals from the time of commencing surgery until discharge from the recovery room.

Induction and maintenance of anaesthesia were done according to a standard protocol. Anaesthesia was induced with propofol titration of 2 to 3 mg/kg, fentanyl 1 µg/kg and muscle relaxation was achieved with rocuronium 1 mg/kg. The trachea was intubated via the nasal route. General anaesthesia was maintained with a mixture of air, oxygen and sevoflurane at 1 to 1.5 MAC. Before the start of the surgical procedures, regional anaesthesia were performed by infiltrating 2.7 mL of 2% lignocaine with 1 in 80,000 adrenaline around the base of the gum of each third molar by the same team of dental surgeons. Sevoflurane was stopped when the last suture had been inserted. andVolume of 1 ml of either dexmedetomidine (Group D, totally dexmedetomidine 1 µg/kg for 4 surgical sites) or saline (Group P) was infiltrated to the submucosa of each surgical site. Neuromuscular block was antagonized with neostigmine 50 µg/kg and atropine 20 µg/kg, and followed by extubation after recovery of consciousness. The patients were then monitored in the recovery room for at least 30 minutes. Resting pain scores, blood pressure, heart rate, oxygen saturation and the Ramsay sedation score (RSS) (appendix 1) were assessed and recorded every 5 minutes. Intravenous ketorolac or morphine would be administered upon patients' request. Patients were transferred back to the general ward when fully consciousness with normal physiological parameters.

The P-deletion test was repeated hourly from the first postoperative hour in the general ward until the performance reached the same level as that before surgery. Blood pressure, heart rate, oxygen saturation, and RSS were monitored hourly for 4 hours. NRS pain scores were charted hourly for 6 hours then 4-hourly thereafter. Patients were prescribed two analgesic tablets, each containing paracetamol 320 mg and dextropropoxyphene 32.5 mg (Dolpocetmol®, Synco Limited, Hong Kong, China), on an as required basis to a maximum of four times daily. The patients were explained told that the pain medications prescribed could be taken if the postoperative NRS pain score was more than 3.

Final hospital discharge was at the discretion of the attending dental surgeon. The oral analgesic medication described above was prescribed for three days postoperatively and patients were given aA diary was given to our patients. diary to record NRS pain scores at rest and upon mouth opening, analgesic consumption and side effects were self recorded by each patient up to the 72nd hour postoperatively. Global pain satisfaction using NRS (zero being least satisfied and 10 being most satisfied) was recorded on postoperative day 3.

By considering a difference of 2 units in NRS pain scores to be clinically significant, and an estimated standard deviation of 2.5 units among patients, we calculated that a sample size of 30 per group would give an 80% power of the test at the 5% level of significance. In order to account for possible dropouts due to protocol violation or missing data, 35 patients were recruited in each group. Statistical analysis was performed using SPSS 14.0 for Windows (SPSS Inc., IL, USA). NRS pain scores, analgesic consumption, NRS global pain satisfaction and the difference in pre- and post-operative P-deletion scores were compared using the Mann-Whitney U test. Perioperative vital signs and NRS pain scores up to the 72nd postoperative 72nd hour were plotted graphically using GraphPad Prism 4.03 (GraphPad Software Inc., CA, USA) and the mean area under the curve AUC were compared between groups using the Mann Whitney U test. All categorical data were analyzed using χ2 test. Time to first analgesic use was compared using the log-rank test in Kaplan-Meier survival analysis. The incidence of side effects was analyzed by χ2 test or Fisher's exact test as appropriate.

Being tested
local dexmedetomidine, Peripheral normal saline, IV dexmedetomidine
Keywords
Analgesia, Dental pain, Dexmedetomidine, Pain, Peripheral effects
Medical subject headings
Agnosia, Toothache, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • local dexmedetomidineDrug

    Also called Precedex

    Preoperative normal saline infusion and 1mcg/kg dexmedetomidine infiltrated locally to wound at the end of operation.

  • Peripheral normal salineDrug

    Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.

  • IV dexmedetomidineDrug

    IV dexmedetomidine 1mcg/kg peroperative and normal saline infiltrated to wound at the end of operation

Study groups in NCT00971178
Study groupRoleWhat they receive
Local DexmedetomidineActive comparatorNot described
Receives: Drug: local dexmedetomidine
Normal SalinePlacebo comparatorNot described
Receives: Drug: Peripheral normal saline
IV dexmedetomidineActive comparatorNot described
Receives: Drug: IV dexmedetomidine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain Score at Rest

    The Numerical Rating Scale (NRS) is used for pain score assessment at rest. It is a scale consists of 11 numbers in which 0 corresponds to no pain and 10 represents the worst pain imaginable. The NRS pain scores over postoperative 72 hours is expressed as Area Under Curve using the trapezoid rule and compared among the 3 groups using the Kruskal-Wallis test.

    Measured: 72 hours after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Sep 2009 (estimated)
  2. Study startFeb 2006
  3. Primary completionMar 2008
  4. Study completionMar 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
105 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00971178
Sponsor's protocol ID
200807176008
Status last verified
Nov 2020
First submitted
1 Sep 2009
Last updated
11 Dec 2020
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing local dexmedetomidine, Peripheral normal saline and IV dexmedetomidine in people with Third Molar Extraction, run by The University of Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 11 Dec 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain Score at Rest (time frame: 72 hours after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Dec 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in